IQVIA Holdings Inc. $IQV Shares Purchased by HF Advisory Group LLC

HF Advisory Group LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 11.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 10,758 shares of the medical research company’s stock after acquiring an additional 1,081 shares during the quarter. HF Advisory Group LLC’s holdings in IQVIA were worth $1,695,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Brighton Jones LLC grew its stake in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. State of Wyoming grew its stake in IQVIA by 52.5% in the 4th quarter. State of Wyoming now owns 851 shares of the medical research company’s stock valued at $167,000 after acquiring an additional 293 shares during the period. Waverly Advisors LLC acquired a new stake in IQVIA in the 4th quarter valued at $626,000. Voloridge Investment Management LLC grew its stake in IQVIA by 325.7% in the 4th quarter. Voloridge Investment Management LLC now owns 194,103 shares of the medical research company’s stock valued at $38,143,000 after acquiring an additional 148,512 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in IQVIA by 13.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company’s stock valued at $273,766,000 after acquiring an additional 167,057 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Robert W. Baird raised their price objective on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Barclays raised their price objective on IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. Mizuho raised their price objective on IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. UBS Group raised their price objective on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Finally, Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $229.64.

IQVIA Stock Up 1.9%

NYSE IQV opened at $190.17 on Friday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $248.03. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The business’s fifty day simple moving average is $184.30 and its 200-day simple moving average is $167.42. The firm has a market cap of $32.33 billion, a PE ratio of 27.52, a P/E/G ratio of 2.05 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.